Tempus AI Gets a $100 Price Target – Why Mizuho Sees Big Upside in Precision Oncology

Mizuho starts coverage on Tempus AI with Outperform rating and $100 price target. Leader in AI-powered precision oncology in a $40B market growing 30% annually—growth undervalued today.